NKGen Biotech, Inc.

Graf Acquisition Corp. IV, trading under the ticker GFOR, is a blank-check company sponsored by Graf Acquisition Corp. that completed its initial public offering in 2021 with a focus on the healthcare and biotechnology sector. The SPAC pursued a business combination with NKGen Biotech, Inc., a clinical-stage biotherapeutics company developing natural killer cell therapies for cancer and neurodegenerative diseases. The August 2021 10-Q filing, carrying accession number 0001104659-21-106424, reflects the company's reporting obligations during its active search and transaction phase. The de-SPAC process brought NKGen Biotech into the public markets under the GFOR vehicle. Visit SpacDesk and sign up for full data, filings history, and deal analytics on GFOR and hundreds of other SPAC transactions.